Cargando…
Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol
BACKGROUND: Metronomic chemotherapy (MC) strategy has been used in breast cancer for more than a decade since it was first proposed. The purpose of this study is to systematically evaluate its efficacy and safety for breast cancer patients at various stages, as well as to clarify the most effective...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202618/ https://www.ncbi.nlm.nih.gov/pubmed/34115017 http://dx.doi.org/10.1097/MD.0000000000026255 |
_version_ | 1783708019477970944 |
---|---|
author | Xie, Ying Chen, Xinjie Li, Bingxue Wang, Xiaoming |
author_facet | Xie, Ying Chen, Xinjie Li, Bingxue Wang, Xiaoming |
author_sort | Xie, Ying |
collection | PubMed |
description | BACKGROUND: Metronomic chemotherapy (MC) strategy has been used in breast cancer for more than a decade since it was first proposed. The purpose of this study is to systematically evaluate its efficacy and safety for breast cancer patients at various stages, as well as to clarify the most effective medication strategy when applying MC and discover its most sensitive subpopulation in breast cancer patients. METHOD: We will systematically retrieve random controlled trials evaluating the efficacy and safety of MC in breast cancer on PubMed, Cochrane Library, Embase, and web of science to perform this network meta-analysis. Markov chain Monte Carlo method based on Bayesian Theory will be used to conduct network meta-analysis and the efficacy and safety will be ranked by combining direct and indirect evidence in mixed treatment comparisons. We will assess the quality of literatures with the Cochrane Risk Bias Assessment Tool and assess the strength of the evidence using the GRADE methodology. Data analysis will be completed with the WinBUGS, R, Stata and RevMan softwares. RESULTS AND CONCLUSION: Through the analysis, we can obtain the ranking of efficacy and safety in different MC strategy, and reveal the specific breast cancer groups that are more sensitive to MC. We access the effectiveness by disease free survival, progress free survival, time to progress, objective response rate, and overall survival, and measure the toxicity by dose-limiting toxicity. The result of our study could provide evidence for clinicians to make a better choice when they consider MC. INPLASY REGISTRATION NUMBER: INPLASY202140142. |
format | Online Article Text |
id | pubmed-8202618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82026182021-06-15 Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol Xie, Ying Chen, Xinjie Li, Bingxue Wang, Xiaoming Medicine (Baltimore) 5750 BACKGROUND: Metronomic chemotherapy (MC) strategy has been used in breast cancer for more than a decade since it was first proposed. The purpose of this study is to systematically evaluate its efficacy and safety for breast cancer patients at various stages, as well as to clarify the most effective medication strategy when applying MC and discover its most sensitive subpopulation in breast cancer patients. METHOD: We will systematically retrieve random controlled trials evaluating the efficacy and safety of MC in breast cancer on PubMed, Cochrane Library, Embase, and web of science to perform this network meta-analysis. Markov chain Monte Carlo method based on Bayesian Theory will be used to conduct network meta-analysis and the efficacy and safety will be ranked by combining direct and indirect evidence in mixed treatment comparisons. We will assess the quality of literatures with the Cochrane Risk Bias Assessment Tool and assess the strength of the evidence using the GRADE methodology. Data analysis will be completed with the WinBUGS, R, Stata and RevMan softwares. RESULTS AND CONCLUSION: Through the analysis, we can obtain the ranking of efficacy and safety in different MC strategy, and reveal the specific breast cancer groups that are more sensitive to MC. We access the effectiveness by disease free survival, progress free survival, time to progress, objective response rate, and overall survival, and measure the toxicity by dose-limiting toxicity. The result of our study could provide evidence for clinicians to make a better choice when they consider MC. INPLASY REGISTRATION NUMBER: INPLASY202140142. Lippincott Williams & Wilkins 2021-06-11 /pmc/articles/PMC8202618/ /pubmed/34115017 http://dx.doi.org/10.1097/MD.0000000000026255 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5750 Xie, Ying Chen, Xinjie Li, Bingxue Wang, Xiaoming Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol |
title | Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol |
title_full | Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol |
title_fullStr | Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol |
title_full_unstemmed | Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol |
title_short | Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol |
title_sort | comparative efficacy and safety of metronomic chemotherapy in breast cancer: a protocol for network meta-analysis protocol |
topic | 5750 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202618/ https://www.ncbi.nlm.nih.gov/pubmed/34115017 http://dx.doi.org/10.1097/MD.0000000000026255 |
work_keys_str_mv | AT xieying comparativeefficacyandsafetyofmetronomicchemotherapyinbreastcanceraprotocolfornetworkmetaanalysisprotocol AT chenxinjie comparativeefficacyandsafetyofmetronomicchemotherapyinbreastcanceraprotocolfornetworkmetaanalysisprotocol AT libingxue comparativeefficacyandsafetyofmetronomicchemotherapyinbreastcanceraprotocolfornetworkmetaanalysisprotocol AT wangxiaoming comparativeefficacyandsafetyofmetronomicchemotherapyinbreastcanceraprotocolfornetworkmetaanalysisprotocol |